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[Abstract] Platelets regulate haemostasis and are the key determinants of pathogenic thrombosis 9 
following atherosclerotic plaque rupture. Platelets circulate in an inactive state, but become activated in 10 
response to damage to the endothelium, which exposes thrombogenic material such as collagen to the 11 
blood flow. Activation results in a number of responses, including secretion of soluble bioactive 12 
molecules via the release of alpha and dense granules, activation of membrane adhesion receptors, 13 
release of microparticles, and externalisation of phosphatidylserine. These processes facilitate firm 14 
adhesion to sites of injury and the recruitment and activation of other platelets and leukocytes, resulting 15 
in aggregation and thrombus formation. Platelet activation drives the haemostatic response, and also 16 
contributes to pathogenic thrombus formation. Thus, quantification of platelet-associated responses is 17 
key to many pathophysiologically relevant processes. Here we describe protocols for isolating, counting, 18 
and activating platelets, and for the rapid quantification of cell surface proteins using flow cytometry.  19 
Keywords: Platelets, Platelet isolation, Platelet activation, Flow cytometry, Platelet enumeration 20 
 21 
[Background] Platelets are small circulating cells with key roles in the normal haemostatic response to 22 
vascular injury, and also in pathogenic thrombus formation resulting from, for example, atherosclerotic 23 
plaque rupture. Both haemostasis and plaque rupture result in exposure of thrombogenic material to the 24 
circulation, including collagen, von Willebrand factor (vWF), and also a variety of soluble platelet 25 
agonists released from damaged cells. Thrombin, generated as part of the coagulation cascade, is a 26 
potent platelet agonist that activates platelets via protease-activated receptors. Once activated, platelets 27 
undergo a number of processes, including shape change, degranulation of alpha and dense granules, 28 
secretion of bioactive molecules (including platelet agonists, such as thromboxane A2, ADP and 29 
serotonin), phosphatidylserine exposure, and receptor activation. Released soluble platelet agonists 30 
regulate autocrine and paracrine activation via GPCR signalling, resulting in the activation and 31 
recruitment of other platelets, and formation of a thrombus (Li et al., 2010). 32 
Activation also results in upregulation of a number of adhesive receptors on the platelet surface. 33 
Principally, activation results in the ‘inside-out’ signalling processes that activate the fibrinogen receptor, 34 
integrin αIIbβ3 (glycoprotein IIb-IIIa), which is responsible for platelet-platelet interactions as a result of 35 
binding to fibrinogen. Activated αIIbβ3 also binds to vWF, further associating platelets to sites of vascular 36 
damage (Bennett, 1996). Activation also results in externalisation of P-selectin, which regulates 37 
leukocyte binding via its ligand P-selectin glycoprotein ligand-1. This results in the formation of platelet-38 
leukocyte aggregates, which are essential for the delivery of pro-inflammatory cytokines to the damaged 39 
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endothelium (Yun et al., 2016). Activation also causes loss of phospholipid asymmetry and exposure of 40 
phosphatidylserine (PS) on the outer leaflet of the membrane. This supports the formation of the 41 
prothrombinase complex (Monroe et al., 2002) and therefore the conversion of prothrombin into active 42 
thrombin (Lane et al., 2005). 43 
In addition to haemostatic roles, soluble factors released from activated platelets also influence other 44 
processes. For example, interleukin-1 from activated platelets has proinflammatory roles in arthritis 45 
(Boilard et al., 2010), and cerebrovascular disease (Thornton et al., 2010). Therefore, the importance of 46 
measuring factors found on the surface and released from activated platelets is important to many areas 47 
of biology.  48 
Here we describe several commonly used protocols that can be used to isolate and activate platelets, 49 
and quantify the proteins they express. These protocols can be easily adapted to look at other proteins 50 
of interest on platelets.  51 
 52 
Materials and Reagents 53 
 54 
1. Glass tubes (Fisher, catalog number: 11852363) 55 
2. Pipette tips (Gilson, catalog number: F167104; F167103; F167101) 56 
3. 1 ml syringe (BD, catalog number: 309628) 57 
4. 10 ml syringe (BD, catalog number: 305959) 58 
5. 50 ml syringe (BD, catalog number: 300865) 59 
6. 0.22 μm syringe filter (Merck, catalog number: SLGP033RS) 60 
7. 21 G syringe needle (Sarstedt, catalog number:  85.1162) 61 
8. 23 G syringe needle (BD, catalog number: 300800) 62 
9. 27 G syringe needle (BD, catalog number: 302200) 63 
10. 14 ml round bottomed tubes (Falcon, catalog number: 352059) 64 
11. 1.5 ml microcentrifuge tubes (Trefflab, catalog number: 96.07811.9.03) 65 
12. 2 ml microcentrifuge tubes (Trefflab, catalog number: 96.09329.01) 66 
13. EDTA coated capillary tube (Sarstedt, catalog number: 16.444) 67 
14. Mouse (Jackson Laboratory, catalog number: 000664) 68 
15. Sodium citrate (Sigma, catalog number: C8532) 69 
16. Atroxin (Sigma, catalog number: 11335) 70 
17. Hank’s Balanced Salt Solution (HBSS) (Sigma, catalog number: H9394) 71 
18. EDTA (Sigma, catalog number: E5134) 72 
19. Calcium Chloride (Sigma, catalog number: C7902) 73 
20. Aggregometry cuvettes (aggregometer specific; e.g. Helena, catalog number: 1473)  74 
21. Cross-linked Collagen related peptide (CRP-XL) Professor Richard Farndale, Dept. 75 
Biochemistry, Cambridge, https://collagentoolkit.bio.cam.ac.uk/thp/generic) 76 
22. Collagen (Helena, catalog number: 5368) 77 
23. Thrombin (Merck, catalog number: 69671-3) 78 
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24. ADP (Sigma, catalog number: A2754) 79 
25. Platelet Activating Factor (Sigma, catalog number: 511075) 80 
26. Platelet surface markers: 81 
a. Anti-human CD41-PE (for detection of Integrin alpha-IIb, Biolegend, clone: HIP8, 82 
catalog number: 303706)  83 
b. Anti-human CD42b-PE (for detection of GPIb, Biolegend, clone: HIP1, catalog number: 84 
303905) 85 
27. Activated platelet markers:  86 
a. PAC-1-FITC (for detection of activated integrin αIIbβ3, Thermofisher, clone: PAC-1, 87 
catalog number: MA5-28564) 88 
b. Anti‐CD62P‐FITC (for detection of alpha granule release, Biolegend, clone: AK4, 89 
catalog number: 304903) 90 
c. Anti-CD63-AF488 (for detection of dense granule release, Thermofisher, clone: MEM-91 
259, catalog number: MA5-18149) 92 
d. Anti-human Annexin V-FITC (Biolegend, catalog number: 640914) 93 
e. Anti-human IL-1α-FITC (R&D, clone: 3405, catalog number: FAB200F) 94 
28. Rat monoclonal anti-mouse CD42b (Emfret, catalog number: R300) 95 
29. Bovine Serum Albumin (Sigma, catalog number: A3059) 96 
30. Phosphate Buffered Saline (Sigma, catalog number: D8537) 97 
31. Sodium Azide (Sigma, catalog number: S2002) 98 
32. β-mercaptoethanol (Sigma, catalog number: M6250) 99 
33. Tris base (Sigma, catalog number: T6066) 100 
34. SDS (Sigma, catalog number: 75746) 101 
35. Bromophenol blue (Sigma, catalog number: 114391) 102 
36. Glycerol (Sigma, catalog number: G5516) 103 
37. Liquid nitrogen 104 
38. Deionised water 105 
39. Serum-free DMEM (Sigma, catalog number: 05671) 106 
40. Calcium-free Tyrode’s buffer (Boston BioProducts, catalog number: BSS-350) 107 
41. Sodium citrate for anticoagulation of blood (see Recipes) 108 
42. Hank’s Balanced Salt Solution (HBSS) with EDTA (see Recipes) 109 
43. FACs buffer (see Recipes) 110 
44. Laemmli buffer (see Recipes) 111 
 112 
Equipment 113 
 114 
1. Pipettes 115 
2. -20 °C freezer 116 
3. Centrifuge with swing out rotor suitable for 15 ml tubes (Eppendorf, model: 5810R) 117 
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4. Sonicator (Diagenode, Bioruptor, model: UCD-200) 118 
5. Accuri flow cytometer (BD, model: C6) 119 
6. Liquid nitrogen dewar 120 
7. Microbalance 121 
8. 37 °C incubator 122 
9. Warming box for rodents (Able Scientific, model ASHE011AR) 123 
10. Mouse restrainer (Braintree Scientific, model: SHORTI STD) 124 
11. Weighing scales 125 
12. AggRAM Aggregometer (Helena Biosciences, model 110/220) 126 
13. Aggregometry cuvettes 127 
14. Protein gel electrophoresis equipment 128 
 129 
Software 130 
 131 
1. C6 Analysis Software (BD Accuri, catalog number: 653122), or other appropriate analysis 132 
software. 133 
 134 
Procedure 135 
 136 
Note: Perform all protocol steps for live platelets at room temperature – do not put platelets on ice. 137 
A. Collection of human blood  138 
Note: Sodium citrate anticoagulation is recommended to produce serum, but other anticoagulants 139 
can be used for these protocols. See Notes section for further details.  140 
1. Draw 9 ml of venous blood into a 10 ml syringe with a 21 G syringe needle from a consenting 141 
adult donor. This should be performed by a competent phlebotomist. 142 
2. Remove needle from syringe and immediately and gently transfer blood into a round bottomed 143 
14 ml centrifuge tube containing 1 ml 3.8% sodium citrate (see Recipes). 144 
3. Mix blood with sodium citrate by gently inverting the tube three times.  145 
 146 
B. Collection of mouse blood  147 
Note: Sodium citrate anticoagulation is recommended to produce serum, but other anticoagulants 148 
can be used for these protocols. See Notes section for further details. 149 
1. Collect 75 µl blood from the mouse dorsal pedal vein, or another venous non-terminal collection 150 
site. For blood collection from the pedal vein, place mouse into a restrainer and puncture the 151 
vein with a 23 G syringe needle. Collect the blood by holding an EDTA coated capillary tube to 152 
the puncture site. Pre-warming the mice greatly aids identification of the pedal vein. 153 
2. Alternatively, collect 900 µl of blood by cardiac puncture under terminal anaesthesia with a 23 154 
G needle and 1 ml syringe. Remove needle from syringe and transfer blood immediately to a 155 
microcentrifuge tube containing 100 µl of 3.8% sodium citrate. 156 
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 157 
C. Enumeration of platelets in whole blood by flow cytometry 158 
Note: Avoid bubbles and transfer of any excess volume during pipetting.  159 
1. Mix whole blood by gently inverting tube several times. 160 
2. Using a 20 µl pipette tip, collect 10 µl of blood. Wipe outside of tip with tissue to remove excess 161 
volume. 162 
3. Add 10 µl of blood to 190 µl of FACs buffer (see Recipes). Wash out pipette tip into buffer by 163 
gently pipetting up and down. 164 
4. Mix well by gently pipetting, and discard 100 µl. Add 0.5 µl of anti-CD41-PE (or other 165 
fluorophore-conjugated platelet marker antibody) to the remaining 100 µl and mix gently. 166 
5. Incubate for 20 min at RT in the dark.  167 
6. Mix well by gently pipetting. 168 
7. Remove 40 µl with a clean pipette tip. Wipe the outside of tip with a tissue to remove excess 169 
blood. Transfer to 1,960 µl of FACs buffer.  170 
8. Mix gently by inverting tube six times. 171 
9. Analyse immediately by flow cytometry, collecting 50 µl with a FSC-H threshold of 25,000 (or 172 
the maximum threshold that removes noise without losing platelet events) on medium speed. 173 
Backflush between each sample and wipe the sample injection port with tissue between 174 
samples to remove any excess volume and blood.  175 
Note: Use counting beads for flow cytometers that cannot perform volume measurements. 176 
10. Display data as FSC-A vs FL2-A (or the appropriate fluorescence channel for the antibody used) 177 
11. Record the count of the positively stained platelet population by adding together the counts from 178 
the platelet gate and the platelet/RBC coincidence gate (Figure 1). 179 
12. The final dilution is 1:1005, so platelet count in blood can be determined using the calculation: 180 
 181 
𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑝𝑝𝑝𝑝𝑐𝑐 ×  �10051 � × � 1𝑣𝑣𝑐𝑐𝑝𝑝𝑐𝑐𝑣𝑣𝑝𝑝 𝑖𝑖𝑐𝑐 µ𝑝𝑝 𝑐𝑐𝑐𝑐𝑝𝑝𝑝𝑝𝑝𝑝𝑐𝑐𝑝𝑝𝑝𝑝𝑐𝑐� = 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 𝑝𝑝𝑝𝑝𝑝𝑝 µ𝑝𝑝 𝑐𝑐𝑜𝑜 𝑏𝑏𝑝𝑝𝑐𝑐𝑐𝑐𝑐𝑐 182 
 183 
Note: If liquid anticoagulant is used, the dilution factor from this will have to be taken into account. 184 
For example, for sodium citrate 1 ml : 9 ml of blood, the value from the above equation needs to be 185 
multiplied by [10/9]. Typical human and mouse platelet count is 150–450 x103/µl, and 1000 x103/µl, 186 
respectively. 187 
 188 
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 189 
Figure 1. Example of results showing analysis of platelet population by flow cytometry. 190 
Whole blood diluted as above was stained with anti-CD41-PE prior to analysis by flow cytometry. 191 
The platelet and platelet/RBC coincidence populations are identified as having higher 192 
fluorescence in FL2. 193 
 194 
D. Production of platelet rich plasma from whole blood 195 
1. Centrifuge whole blood for 20 min at 350 x g, RT. 196 
2. The blood will have separated into two layers: the lower, dark layer of packed red blood cells, 197 
and the upper yellow layer of platelet rich plasma (PRP). The PRP volume will be approximately 198 
50% of the whole blood volume. 199 
3. Carefully remove the upper PRP layer and transfer to a new round bottomed centrifuge tube. 200 
4. PRP may be used directly in aggregometry experiments. Further processing is required to 201 
provide serum, or to generate washed platelet suspensions. 202 
Note: Platelets will be more concentrated in PRP than in whole blood. If the platelet count in 203 
PRP is required to make lysates or for platelet activation, the “enumeration of platelets in whole 204 
blood by flow cytometry” protocol may be used, using 10 µl of PRP at Step C3 instead of whole 205 
blood.  206 
 207 
E. Production of platelet poor plasma from platelet rich plasma 208 
1. To generate platelet poor plasma (PPP), centrifuge PRP for 10 min at 2,000 x g, RT. 209 
2. The PRP will have separated into an upper pale yellow layer (PPP) and a platelet pellet. 210 
Carefully remove the upper PPP layer, avoid disturbing the platelet pellet. 211 
3. PPP may be used as a control for aggregometry assays (see Section F), and to adjust PRP 212 
concentration. It may also be used to make PPP-derived serum, which lacks factors released 213 
from activated platelets.  214 
 215 
F. Aggregometry for assessment of platelet function  216 
1. Aliquot 250 µl of PPP into a glass aggregometry cuvette containing a stir bar. 217 
2. Insert the cuvette into the aggregometer and take a reading. This will calibrate the aggregometer 218 
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to 100% aggregation. Remove the cuvette. 219 
3. Aliquot 250 µl of PRP or washed platelet suspension into a fresh aggregometry cuvette 220 
containing a stir bar. The concentration of platelets in washed platelet suspensions should be 221 
adjusted to a standardised level, with a recommended concentration of 2x108/ml, in calcium free 222 
Tyrode’s buffer. For experiments using PRP, the platelet concentration can be adjusted using 223 
platelet poor plasma (PPP). 224 
4. Insert the cuvette into the aggregometer and begin recording changes in light transmission. 225 
5. After 30 s, add an agonist (see Table 1 below). Keep recording changes in light transmission for 226 
15 min. Agonist concentrations should be adjusted to ensure that the volume of agonist does 227 
not exceed 1/100 of the platelet volume. Varying the agonist concentration can reveal 228 
information about the sensitivity of platelets to different agonists. 229 
Note: Recommended volumes may vary depending on aggregometer model, use volumes 230 
according to manufacturer’s recommendation.  231 
 232 
 233 
 234 
 235 
 236 
 237 
 238 
 239 
 240 
 241 
 242 
 243 
 244 
 245 
 246 
 247 
Figure 2. Representative aggregometry trace. The above aggregometry trace shows 248 
increased light transmission through a washed platelet suspension as they aggregate in 249 
response to 1 µg/mL CRP-XL. 250 
 251 
G. Production of serum from blood anticoagulated with sodium citrate 252 
1. For production of serum from PRP, add 22 µl of 1 M CaCl2 to 1 ml of PRP and incubate in a 253 
glass tube at 37 °C until a clot forms and retracts away from the sides of the tube. This takes 254 
approximately 30-45 minutes. Transfer the liquid phase (serum) into a clean microcentrifuge 255 
tube and store at -20 °C.  256 
2. For production of serum from PPP, add 22 µl of 1 M CaCl2 to 1 ml of PPP and incubate at 37 °C 257 
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until coagulated. Coagulated PPP will form a loose clot that does not retract. Centrifuge the 258 
coagulated PPP at 10,000 x g for 1 min and transfer the upper liquid layer (serum) into a clean 259 
microcentrifuge tube. Store at -20 °C. 260 
 261 
H. Platelet washing 262 
1. Wash platelets by diluting PRP (see section D) with 5 volumes of calcium-free HBSS, 263 
supplemented with 4 mM EDTA, pH 6.4 (see Recipes). 264 
2. Centrifuge for 20 min at 350 x g, RT. 265 
3. Washed platelets can be resuspended directly into media suitable for experiment. 266 
Note: A low level of leukocytes will be present in washed platelets. Repeated rounds of the 267 
washing protocol will reduce leukocyte contamination.  268 
 269 
I. Platelet activation assays: preparation of platelets for flow cytometry or lysate production 270 
1.  In order to produce results that are comparable with platelet aggregometry, conduct these 271 
experiments in an aggregometry cuvette under stirred conditions. 272 
2. Following centrifugation of platelets (see Section H), gently resuspend the platelet pellet into 273 
calcium-free, EDTA-free HBSS, pH 6.4 (see Recipes). Dilute platelets to 4 x 108/ml (giving 8 x 274 
106 platelets in a working volume of 20 μl), adjust volumes according to number of conditions 275 
and replicates.  276 
3. Activate platelets by the addition of platelet agonists (see Table 1 for examples). Ensure that 277 
you include a vehicle control. 278 
4. Stain platelets for flow cytometry, or make lysates for Westerns, etc.  279 
 280 
Table 1. Examples of platelet agonists and concentrations for platelet activation 281 
Platelet agonist Final 
concentration 
Suggested 
incubation time 
Suggested incubation 
temperature 
Collagen 5 µg/ml 15 min 37 °C 
Collagen-related 
peptide (CRP)-XL 
50 µg/ml 15 min 37 °C 
Thrombin 1 U/ml 1 min 37 °C 
ADP 10 µM 1 min 37 °C 
Platelet Activating 
Factor 
0.3 µM 4 min 37 °C 
 282 
J. Generation of platelet lysates for ELISA 283 
1. Following platelet activation, resuspend 8 x 108 platelets in 400 μl of serum-free DMEM. Adjust 284 
volumes according to platelet number. Use protease, phosphatase, etc, inhibitors if required. 285 
2. Freeze-thaw tubes three times using liquid nitrogen. Submerse the tube in liquid nitrogen to 286 
freeze completely, before removing and allowing to defrost completely at room temperature. 287 
3. Sonicate lysates three times for 30 s on ice. 288 
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4. Centrifuge for 3 min at 13,000 x g, RT to pellet debris. Transfer supernatant to a clean 289 
microcentrifuge tube. 290 
5. Store at -20 °C until use. 291 
 292 
K. Making platelet lysates for Western Blot 293 
1. Following platelet activation, resuspend 3 x 108 platelets directly into 100 μl of 1x Laemmli buffer. 294 
2. Heat at 95 °C for 5 min, then cool on ice. 295 
3. Load 10 μl for 3 x 107 platelets per lane of an SDS-PAGE mini gel. 296 
 297 
L. Platelet staining for flow cytometry 298 
1. Stain platelet suspensions for surface proteins of interest using any standard staining protocol 299 
for flow cytometry. Keep platelets at room temperature at all times. Handling a platelet pellet 300 
from small volumes is difficult, so protocols that avoid washing steps are preferable to avoid 301 
losing platelets during supernatant aspiration.  302 
2. Co-stain 10 µl of control or activated platelets with a platelet surface marker and platelet 303 
activation marker of interest (see Tables 2 and 3 for examples). 304 
3. Dilute platelet suspensions with FACs buffer to 120 µl (see Recipes). 305 
4. Analyse platelets by flow cytometry ensuring the FSC acquisition threshold is sufficiently low to 306 
recognise the whole platelet population, whilst excluding noise (see Notes).  307 
 308 
Table 2. Examples of antibodies for platelet marker staining 309 
Platelet surface 
markers 
Example antibody Suggested 
dilution 
Suggested 
duration 
CD41 (Integrin αIIb) Anti-human CD41-PE 
(Biolegend, 303706) 
1:25 30 min 
CD42b (GPIb) Anti-human CD42b-PE 
(Biolegend, 303905) 
1:20 30 min 
 310 
Table 3. Examples of antibodies used to quantify platelet activation markers  311 
Platelet activation marker Example antibody/protein Suggested 
dilution 
Suggested 
duration 
P-selectin (CD62P, detects 
alpha granule secretion) 
Anti-human CD62P-FITC (Biolegend, 
304903) 
1:20 30 min 
CD63 (detects dense granule 
secretion) 
Anti-human CD63 Alexa fluor 488 
(Thermofisher, MA5-18149) 
1:25 30 min 
Activated αIIbβ3 Anti-human PAC-1 (Thermofisher, 
MA5-28564) 
1:25 30 min 
Annexin V (binds to PS) Anti-human Annexin V FITC kit 
(Biolegend, 640914). Use included 
buffer. Ca2+ dependent binding.  
1:20 15 min 
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Interleukin-1α Anti-human IL-1α-FITC (R&D, 
FAB200F) 
1:20 30 min 
 312 
M. Platelet depletion in mice 313 
Note: Platelets may be depleted in vivo by administration of anti-CD42b, which targets platelets for 314 
clearance.  315 
1. Determine the baseline platelet count in mice by collecting blood (~20 µl) from the pedal vein 316 
(see Section B), and platelet enumeration by flow cytometry (see Section C). 317 
2. Weigh mice using scales.  318 
3. Prepare anti-CD42b so that each mouse receives 1.8 µg/g body weight in 100-200 µl of sterile 319 
PBS. For example, for a single 25 g mouse, add 75 µl of PBS to 125 µl of 0.5 mg/ml anti-CD42b 320 
stock to achieve a working solution of 0.31 mg/ml and administer 147 µl. Use sterile PBS only 321 
as a vehicle control.  322 
4. Place mice into a warming box for rodents at 37 °C for 15 min to facilitate dilation of veins. 323 
5. Place mouse into a restrainer and administer anti-CD42b or vehicle control by intravenous tail 324 
vein injection with a 27 G needle. Hold the injection site under pressure until bleeding subsides. 325 
6. Repeat pedal vein blood sampling and platelet counts at the frequency required.  326 
Note: Bleeding at sampling sites will be prolonged while the platelet count is low, so apply 327 
pressure for at least ten minutes and monitor haemostasis carefully.  328 
 329 
A SCHEMATIC OVERVIEW OF THESE PROCESSES IS SHOWN BELOW 330 
 331 
Figure 3: Schematic overview of the processes outlined in these protocols.  332 
                 
11 
www.bio-protocol.org/exxxx   
Bio-protocol 9(xx): exxxx. 
DOI:10.21769/BioProtoc.xxxx 
 
Data analysis 333 
 334 
1. Collect events on plot using FSC-A and SSC-A parameters (Figure 4). 335 
2. Plot PE fluorescence intensity (platelet marker +ve events) on a logarithmic scale against FITC 336 
fluorescence intensity (platelet activation marker +ve events).  337 
3. Use quadrant gating on the control samples to restrict the CD41-positive control platelet 338 
population to the upper left quadrant.  339 
4. PE+/FITC+ populations will appear in the upper right quadrant for any conditions resulting in 340 
double positive staining.  341 
5. Calculate median fluorescence intensity (MFI) of upper left and upper right quadrants. To 342 
remove background, subtract the MFI of unstained cells from the stained cells.  343 
6. Calculate the mean MFI from duplicates of each condition. 344 
7. Data can also be analysed as percentage of total cell population. For this, calculate percentage 345 
population of interest by dividing PE+/FITC+ events (upper right gate) by PE+ events (upper left 346 
and upper right gates) and multiply by 100. 347 
 348 
 349 
Figure 4. Example of changes in activation state of platelets following stimulation with 350 
collagen. Platelets were prepared as above and stimulated with collagen prior to co-labelling 351 
with a PE-conjugated platelet marker (in this case CD41), and a FITC-conjugated platelet 352 
activation marker/protein of interest (in this case cell-surface IL-1α). Treatment with collagen 353 
results in a rightward shift in FITC-positive platelets. 354 
 355 
                 
12 
www.bio-protocol.org/exxxx   
Bio-protocol 9(xx): exxxx. 
DOI:10.21769/BioProtoc.xxxx 
 
Notes 356 
 357 
1. Platelets are sensitive and should be handled gently to avoid activation. Whole blood, platelet 358 
rich plasma, and washed platelets should be kept at room temperature at all times unless 359 
indicated (i.e., 37 °C). 360 
2. Sodium citrate is the recommended anticoagulant for these protocols, as its chelation of divalent 361 
cations is reversible with the addition of CaCl2, allowing for the easy production of serum. These 362 
protocols can also be performed using other non-reversible anticoagulants if necessary. If serum 363 
is required, the addition of atroxin (Bothrops atrox venom) to a final concentration of 750 ng/ml 364 
will cleave fibrinogen to fibrin and remove it from the plasma (Karapetian, 2013; Wentzensen et 365 
al., 2011). 366 
3. The detection of small particles by flow cytometry (including platelets) depends on accurately 367 
differentiating them from debris and electronic noise. For the Accuri C6 an FSC-H threshold of 368 
~10,000 and medium flow rate was suitable to detect the platelet population.  369 
 370 
Recipes 371 
 372 
1. Sodium citrate for anticoagulation of blood 373 
a. Prepare a 3.8% solution of sodium citrate by dissolving 380 mg sodium citrate in 7 ml water 374 
b. Adjust pH to 7 with concentrated hydrochloric acid 375 
c. Add water to final volume of 10 ml 376 
d. Store solution at 2-8 °C for 6 months. Allow solution to reach room temperature before use.  377 
e. To anticoagulate blood with 0.38% sodium citrate final concentration, add 1 ml of 3.8% 378 
sodium citrate solution to 9 ml of whole blood. Adjust volume of sodium citrate according to 379 
final blood volume 380 
2. Hank’s Balanced Salt Solution (HBSS) with EDTA 381 
a. Add 250 µl of 1M EDTA to 50 ml of HBSS and mix well 382 
b. Adjust pH to 6.4 with concentrated hydrochloric acid 383 
c. Store solution at 2-8 °C for 2 weeks. Allow solution to reach room temperature before use. 384 
3. FACs buffer 385 
a. Dissolve 0.5 g of BSA in 50 ml of PBS 386 
b. Add 250 µl of 10% Sodium Azide solution (0.5 g Sodium Azide dissolved in 5 ml deionised 387 
water) 388 
c. Filter through a 0.22 μm syringe filter prior to use 389 
d. Store solution at -20 °C for 6 months. Allow solution to reach room temperature before use. 390 
4. 1 x Laemmli buffer 391 
To a 15 ml tube, add: 392 
0.8 ml Tris 1 M, pH adjusted to 6.8 393 
1 ml 20% SDS in deionised water 394 
                 
13 
www.bio-protocol.org/exxxx   
Bio-protocol 9(xx): exxxx. 
DOI:10.21769/BioProtoc.xxxx 
 
1 ml glycerol 395 
0.53 ml β-mercaptoethanol 396 
5 mg bromophenol blue 397 
Adjust to 10 ml with deionised water 398 
Store solution at 2-8 °C for 3 months.  399 
 400 
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